Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $38,837 | $49,604 | $48,318 | $43,847 |
| % Growth | -21.7% | 2.7% | 10.2% | – |
| Cost of Goods Sold | $12,802 | $14,822 | $12,047 | $9,622 |
| Gross Profit | $26,035 | $34,782 | $36,271 | $34,225 |
| % Margin | 67% | 70.1% | 75.1% | 78.1% |
| R&D Expenses | $69,353 | $53,370 | $70,923 | $76,377 |
| G&A Expenses | $44,954 | $43,279 | $49,043 | $57,297 |
| SG&A Expenses | $44,954 | $43,279 | $49,043 | $57,297 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,745 | $3,674 | $5,273 | $4,157 |
| Operating Expenses | $116,052 | $100,323 | $125,239 | $137,831 |
| Operating Income | -$90,017 | -$65,541 | -$88,968 | -$103,606 |
| % Margin | -231.8% | -132.1% | -184.1% | -236.3% |
| Other Income/Exp. Net | $9,263 | $4,958 | -$1,901 | -$4,253 |
| Pre-Tax Income | -$80,754 | -$60,583 | -$90,869 | -$107,859 |
| Tax Expense | $1 | -$283 | $88 | -$325 |
| Net Income | -$80,755 | -$60,300 | -$90,957 | -$107,534 |
| % Margin | -207.9% | -121.6% | -188.2% | -245.2% |
| EPS | -1.45 | -1.1 | -1.68 | -2.07 |
| % Growth | -31.8% | 34.5% | 18.8% | – |
| EPS Diluted | -1.45 | -1.1 | -1.68 | -2.07 |
| Weighted Avg Shares Out | 55,634 | 54,859 | 54,242 | 51,895 |
| Weighted Avg Shares Out Dil | 55,634 | 54,859 | 54,242 | 51,895 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,742 | $6,083 | $6,081 | $7,337 |
| Interest Expense | $0 | $0 | $0 | $94 |
| Depreciation & Amortization | $14,168 | $15,793 | $15,366 | $15,652 |
| EBITDA | -$66,586 | -$46,074 | -$68,329 | -$143,484 |
| % Margin | -171.4% | -92.9% | -141.4% | -327.2% |